血清血管内皮生长因子与肾细胞癌临床状态的相关性

Correlation of Serum Vascular Endothelial Growth Factor with Clinical Status of Renal Cell Carcinoma

目的 检测肾细胞癌 (RCC)患者血清血管内皮生长因子 (VEGF)的水平 ,评价其临床意义。方法 用夹心ELISA方法检测 6 1例RCC患者和 4 0例非肿瘤对照者治疗前的外周血血清样本中的VEGF水平和 30例RCC患者肾切除术后 6周的血清VEGF水平。结果 RCC患者血清VEGF水平 [(32 7.77± 2 83.34) pg/mL]显著高于对照者 [(12 4 .73± 5 4 .5 1) pg/mL],不同临床分期的RCC患者血清VEGF水平存在显著差异。术后VEGF水平较术前明显降低。结论 血清VEGF是RCC的潜在标记物 。

Purpose. To investigate the serum vascular endotheial growth factor(VEGF) level in patients with renal cell carcinoma(RCC) so as to evaluate the clinical significance of VEGF in RCC. Methods. Serum VEGF in peripheral blood samples was analyzed in 61 RCC patients at various stages and 40 controls without cancer using a sandwich enzyme-linked immunoadsordent assay. Serum VEGF was also measured before and 6 weeks after nephrectomy in 30 RCC patients. Results. Serum VEGF level in RCC patients was significantly higher than that in the controls[(327.77 ± 283.34) vs (124.73 ± 54.51)pg/mL), mean ± SE]. There was significant differences between the serum VEGF level of patients with invasive(T3 - 4) and non-invasive(T1 - 2) tumors[(532.61 ± 387.49) vs (212.21 ± 76.05) pg/mL], and between that of the patients with and without distant metastasis [(664.36 ± 470.30 vs (245.34 ± 120.02)pg/mL]. The mean serum VEGF level in 30 RCC patients decreased significantly after nephrectomy [from(210.23 ± 89.29) to (118.83 ± 42.30)pg/mL]. Conclusions. Serum VEGF is a potential marker of RCC, and may be useful to predict the prognosis and to monitor the status of RCC.